We suggest that although the anti-FXa test should be used to dose LMWH’s in patients with unpredictable pharmacokinetics: children, the obese, those in renal failure; more functional tests of anticoagulation are required to monitor the actual effect of these drugs [18,19]. The gene discussed is F10; the disease is acute kidney injury.